COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Progress in Medicinal Chemistry - 1st Edition - ISBN: 9780444642776, 9780444642783

Progress in Medicinal Chemistry, Volume 58

1st Edition

0.0 star rating Write a review
Serial Editors: David Witty Brian Cox
Hardcover ISBN: 9780444642776
eBook ISBN: 9780444642783
Imprint: Elsevier
Published Date: 18th March 2019
Page Count: 197
Sales tax will be calculated at check-out Price includes VAT/GST
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

1. Covalent binders in drug discovery
Maria A. Argiriadi, Aleksandra Baranczak, Michael M. Friedman, Julia Gavrilyuk, Adrian D. Hobson, Jonathan J. Hulce, Sami Osman, Noel S. Wilson and Anil Vasudevan
2. Amyotrophic lateral sclerosis
Klara Valko and Lukasz Ciesla
3. Rewriting the (tran)script: Application to spinal muscular atrophy
Hasane Ratni, Lutz Mueller and Martin Ebeling
4. Natural product drug delivery: A special challenge?
Neil J. Press, Emilie Joly and Peter Ertl


Progress in Medicinal Chemistry, Volume 58, provides a review of eclectic developments in medicinal chemistry, with each chapter written by an international board of authors. Topics covered in this new release include Amyotrophic lateral sclerosis (ALS), Covalent-binding Drugs, Natural Product Drug Delivery – A Special Challenge?, and SMN2 gene splicing modifier, and more.

Key Features

  • Provides extended, timely reviews of topics in medicinal chemistry
  • Contains targets and technologies relevant to the discovery of tomorrow’s drugs
  • Presents analyses of successful drug discovery programs


Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes


No. of pages:
© Elsevier 2019
18th March 2019
Hardcover ISBN:
eBook ISBN:

Ratings and Reviews

About the Serial Editors

David Witty

David Witty

Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.

In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.

David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.

Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.

Affiliations and Expertise

WITNET LTD, Cambridge, UK

Brian Cox

Professor Brian Cox is at University of Sussex, Brighton, UK

Affiliations and Expertise

University of Sussex, Brighton, UK